| | Normal flow group | Slow/no reflow group | P value | | n=124 | n=29 | |
| Male gender, n (%) | 96(77.4) | 25(86.2) | 0.295 | Age, years | 63±14 | 61±13 | 0.423 | Cigarette smoking, n (%) | 60(48.4) | 16(55.2) | 0.511 | Heart rate | 83±13 | 86±14 | 0.248 | Systolic blood pressure, mmHg | 129±20 | 123±18 | 0.159 | Diastolic blood pressure, mmHg | 80±14 | 84±19 | 0.306 | Shock index | 0.65±0.09 | 0.71±0.09 | 0.003 | Shock index≥0.66, n (%) | 51(41.1) | 22(75.9) | 0.001 | Diabetes mellitus, n (%) | 34(27.4) | 8(27.6) | 0.986 | Hypertension, n (%) | 65(52.4) | 16(55.2) | 0.789 | Hyperlipidemia, n (%) | 31(25.0) | 10(34.5) | 0.299 | Previous cerebrovascular disease, n (%) | 15(12.1) | 5(17.2) | 0.459 | Time to reperfusion (hour) | 7.63±5.90 | 7.52±5.65 | 0.926 | STEMI, n (%) | 84(67.7) | 21(72.4) | 0.625 | Initial TIMI flow 0/1 grade, n (%) | 95(76.6) | 26(89.7) | 0.120 | High thrombus burden, n (%) | 44(35.5) | 20(69.0) | 0.001 | Preoperative use of tirofiban, n (%) | 75(60.5) | 17(58.6) | 0.854 | Aspiration, n (%) | 24(19.4) | 6(20.7) | 0.871 | Infarct-related coronary artery | | | 0.357 | LAD, n (%) | 62(50.0) | 15(51.7) | | RCA, n (%) | 41(33.1) | 12(41.4) | | LCA, n (%) | 21(16.9) | 2(6.9) | | Killip classification | | | 0.034 | 1/2, n (%) | 112(90.3) | 22(75.9) | | 3/4, n (%) | 12(9.7) | 7(24.1) | | Multivessel disease, n (%) | 60(48.4) | 15(51.7) | 0.746 | Stent diameter, mm | 3.07±0.30 | 3.17±0.35 | 0.100 | Stent length, mm | 35±15 | 34±17 | 0.677 | Maximal balloon pressure, atm | 13±3 | 14±3 | 0.085 | LVEF after PCI, % | 54±9 | 49±8 | 0.024 | In-hospital medication | | | | Aspirin, n (%) | 123(99.2) | 28(96.6) | 0.259 | Clopidogrel or ticagrelor, n (%) | 123(99.2) | 28(96.6) | 0.259 | ACEI or ARB, n (%) | 74(59.7) | 17(58.6) | 0.917 | β-Blockers, n (%) | 54(43.5) | 10(34.5) | 0.373 | Statins, n (%) | 118(95.2) | 27(93.1) | 0.654 | In-hospital outcomes, n (%) | 2(1.6) | 5(17.2) | <0.001 |
|
|